Alzheimer's & Cognition
Conference Coverage
Positive functional results reported for aducanumab in a pooled, post hoc analysis
SAN DIEGO – The results might give patients “an extra year or 2” of independence, said one clinical investigator in an aducanumab trial.
From the Journals
‘Brain enhancement’ supplements sold online may illegally contain piracetam
So-called cognitive enhancement supplements sold online may contain high doses of the nootropic drug piracetam.
From the Journals
Alzheimer’s disease subtypes follow neuropathologic patterns seen in the nucleus basalis of Meynert
Feature
Seaweed floats to the top of Alzheimer’s news
Chinese regulators have approved sodium oligomannate, an extract of brown algae, as a treatment for mild to moderate Alzheimer’s. But questions...
News
Survey asks adults: How likely are you to develop dementia?
Adults are worried about dementia and will do anything to prevent it. Except talk to their doctor.
Feature
Medicare beneficiaries pay most for Alzheimer’s
Long-term care takes a toll on beneficiaries with Alzheimer’s and Parkinson’s disease.
Evidence-Based Reviews
Neuropsychological testing: A useful but underutilized resource
How to work with a neuropsychologist to fine-tune your diagnosis and treatment.
Conference Coverage
Blood test might rival PET scan for detecting brain amyloidosis
ST. LOUIS – A blood test that measures the plasma ratio of amyloid-beta 42 peptide to amyloid-beta peptide 40 can accurately screen cognitively...
Feature
Dr. Paul Aisen Q&A: Aducanumab for Alzheimer’s
A leading Alzheimer’s researcher, Dr. Aisen answers some questions about the resurrection of aducanumab as a potential therapy for Alzheimer’s...
Feature
Biogen plans to submit application to FDA for Alzheimer’s drug aducanumab
The company’s hopes lie with a secondary analysis of high-dose patients from two failed trials.
Conference Coverage
Certain diabetes drugs may thwart dementia
COPENHAGEN – Intriguing findings from a Danish national registry study.